Artielle ImmunoTherapeutics
PrivateLast Round
Series A
Jun 28, 2004
Total Funding Raised
$21M
Momentum
Top 25%
of companies Caplight tracks
Company Overview
Artielle ImmunoTherapeutics operates in Healthcare & Life Sciences and is based in Tigard, Oregon. Its latest recorded funding round was a Series A round in June 2004.
Artielle ImmunoTherapeutics is a biotechnology company that develops a platform of biologic drugs to treat inflammatory and degenerative diseases.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Artielle ImmunoTherapeutics Comparables
Compare Artielle ImmunoTherapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Innovimmune Biotherapeutics | 79% | |
| NervGen Pharma Corp. | 76% | |
| Find Therapeutics | 72% |
For institutional investors. Book with your work email.
Artielle ImmunoTherapeutics Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Artielle ImmunoTherapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Pelion Venture Partners | Series A |
| NIH RADx | Grant |
| Northwest Technology Ventures | Series A |
| U.S. Department of Veterans Affairs | Grant |
| Sanderling Ventures | Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 22, 2026
Monthly visitors increased 555% MoM.
For institutional investors. Book with your work email.
Artielle ImmunoTherapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Artielle ImmunoTherapeutics's valuation, stock price, and market status.
Is Artielle ImmunoTherapeutics a public or private company?
Artielle ImmunoTherapeutics is a private company.
What is the current stock price of Artielle ImmunoTherapeutics?
Artielle ImmunoTherapeutics is a private company, so its shares have no public market price. Caplight tracks Artielle ImmunoTherapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Artielle ImmunoTherapeutics worth (valuation)?
Valuation information for Artielle ImmunoTherapeutics is not publicly available.
Can I buy Artielle ImmunoTherapeutics stock?
Artielle ImmunoTherapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Artielle ImmunoTherapeutics's last funding round?
Artielle ImmunoTherapeutics's most recent funding round was Series A on June 28, 2004.
Who are the main investors in Artielle ImmunoTherapeutics?
Key investors in Artielle ImmunoTherapeutics include Sanderling Ventures.
Will Artielle ImmunoTherapeutics IPO soon?
No public IPO plans have been announced for Artielle ImmunoTherapeutics.
How can I track Artielle ImmunoTherapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Artielle ImmunoTherapeutics's shares on secondary markets.